SigTuple, an inventive Medtech Startup has successfully raised Rs.33 crore (approximately $4million) in its extended Series C Funding round directed by SIDBI Venture capital along with the participation from its current financial backers Endiya Partners and some other strategic industrial leaders from the healthcare landscape.

Earlier, the Bengaluru-based startup had lifted $4.3 million in its Series C funding round directed by Endiya Partners & Accel in the month of March 2023. To date the company has bagged more than $40 million.

According to the press release released by SigTuple, the newly raised funds will be utilized to maximize the geographical extension and extend its product portfolio and nurture regulatory clearances.

Partnering with Horiba Medical as its South Asia distribution channel, SigTuple has also expanded into Southeast Asia, the Middle East, and North Africa, and plans to enter Europe and the Americas. In September 2023, AI100 received US FDA 510(k) approval, making SigTuple the third company globally—and the first in India—to achieve this for AI-assisted digital haematology.

Established by Apurv Anand, Bharath Cheluvaraju, Rohit Kumar Pandey & Tathagato Dastidar in the year 2015, SigTuple builds AI-powered smart robotic microscopes ti automate the manual tasks in the clinical laboratories.

From 2020, SigTuple has concentrated on its key product AI100 which is today achieving significant attention in the Indian market with key diagnostics industry performers as users.

Tathagato Rai Dastidar, Founder & CEO of SigTuple says “While we continue to build on the success of AI100 in India and abroad, 2024 will witness two new major product launches addressing a wide segment of the diagnostic industry, which will help make SigTuple a global brand coming out of India. We are truly excited to welcome SIDBI Venture Capital on board as the lead investor in this round. Their support is going to go a long way in making our dream of going global a reality.”